Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sildenafil
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sildenafil is a small molecule drug classified as a phosphodiesterase type 5 (PDE5) inhibitor. It was originally developed by Pfizer and is primarily indicated for the treatment of erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). In ED, sildenafil works by inhibiting PDE5 in the corpus cavernosum of the penis to increase cyclic guanosine monophosphate (cGMP), resulting in smooth muscle relaxation and increased blood flow during sexual stimulation. For PAH, it relaxes blood vessels in the lungs to reduce pulmonary blood pressure and improve exercise capacity. Sildenafil does not cause an erection without sexual stimulation[1][2][3][4][5].
- Brand names
- ViagraRevatioAronixLiberizeNipatraGrandipamVizarsinLiqrev
- Other names
- sildenafil
02
Targets
PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on sildenafil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sildenafil.